OpenScience.ink

4 weeks ago • Diabetes, obesity & metabolism

Real-World Use of Semaglutide for Weight Loss: How Doses Are Adjusted, Stopped, and Linked to Weight ChangesReal-World Use of Semaglutide for Weight Management: Dose Titration, Discontinuation Patterns and Weight Changes.

4 weeks ago • Cutis

How GLP-1 Receptor Agonists May Affect Hidradenitis Suppurativa: A Complete ReviewThe Effect of GLP-1 Receptor Agonists on Hidradenitis Suppurativa: A Comprehensive Systematic Review.

4 weeks ago • Internal and emergency medicine

GLP-1 Receptor Agonists in Preventing and Treating Cancers Linked to ObesityRole of GLP-1 receptor agonists in the prevention and treatment of obesity-related cancer.

4 weeks ago • Frontiers in bioscience (Landmark edition)

Semaglutide changes fat metabolism in internal belly fat of mice with type 2 diabetesSemaglutide Modulates Visceral Adipose Tissue Lipid Metabolism in Type 2 Diabetic Mice: A Lipidomics Study.

📖 Top 30% Journal

4 weeks ago • Cell metabolism

GLP-1 and Fatty Liver Disease: Effects Beyond Weight LossGLP-1 and MASH: When weight loss isn't the whole story.

🥇 Top 1% Journal

4 weeks ago • Cardiovascular diabetology

Glucagon-like peptide-1 drugs and major limb problems in adults with type 2 diabetes and artery diseaseGlucagon-like peptide-1 receptor agonists and major limb events in adults with type 2 diabetes and peripheral artery disease: a systematic review and meta-analysis of RCTs and cohort studies.

🥈 Top 2% Journal

4 weeks ago • Cell metabolism

A liver enzyme changes gut stem cells to increase high blood sugarA liver phosphatase reprograms gut stem cells to drive hyperglycemia.

🥇 Top 1% Journal

4 weeks ago • International journal of obesity (2005)

Use and Interest in GLP-1 Medications in a Representative Survey of FinnsGLP-1 medications: use and interest in a representative survey of Finns.

🎖️ Top 10% Journal

4 weeks ago • Aesthetic plastic surgery

Computer Study of Preventive Biostimulator Treatments to Reduce Facial Sagging Linked to Weight Loss from GLP-1 DrugsComputational Trial of Prophylactic Biostimulator Interventions to Mitigate Facial Sagging Associated With GLP-1 Receptor Agonist Induced Weight Loss.

📖 Top 20% Journal

4 weeks ago • Cell reports. Medicine

Preventive semaglutide and tirzepatide treatments do not change Alzheimer's disease progression in a mouse modelPreventative semaglutide and tirzepatide treatment does not alter disease progression in the 5xFAD mouse model of Alzheimer's disease.

🥈 Top 2% Journal

4 weeks ago • Drugs

Ecnoglutide: First Official ApprovalsEcnoglutide: First Approvals.

🥈 Top 2% Journal

4 weeks ago • The Journal of rheumatology

Influencing Metabolism and Inflammation in Psoriasis and Psoriatic Arthritis Using Diet, Diabetes Drugs, and Patient ViewsTargeting the Metabolic-Inflammatory Axis in Psoriasis and Psoriatic Arthritis: Evidence From Diet, Glucagon-like Peptide-1 Receptor Agonists, and Patient Perspectives.

1 month ago • Gastro hep advances

Glucagon-Like Peptide-1 Receptor Agonists and Pain Relief in Long-Term PancreatitisThe Effect of Glucagon-Like Peptide-1 Receptor Agonists on Pain Management in Chronic Pancreatitis: A Real-World Cohort Study.

📖 Top 50% Journal

1 month ago • Gastro hep advances

Glucagon-Like Peptide-1 Receptor Drugs and Their Role in Inflammatory Bowel DiseaseGlucagon-Like Peptide-1 Receptor Agonists in Inflammatory Bowel Disease: A Narrative Review.

📖 Top 50% Journal

1 month ago • Cureus

How Orforglipron compares to other GLP-1 receptor agonist drugsComparative Positioning of Orforglipron Among Selected GLP-1 Receptor Agonist Benchmarks: A Narrative Review.

1 month ago • Clinical case reports

Small Bowel Blockage Possibly Caused by Tirzepatide in a Patient Without Prior SurgeryTirzepatide-Induced Functional Small Bowel Obstruction in a Surgically Naïve Patient: A Case Report.

1 month ago • Diabetes, obesity & metabolism

Weight Loss and Major Safety Risks Linked to GLP-1 Receptor Agonist Drugs: A Study Across Multiple CentersGLP-1 Receptor Agonists for Weight Loss and Risk of Major Safety Outcomes: A Multicentre Cohort Study.

1 month ago • Cureus

How Fructose and FTO Gene Differences May Influence the Effectiveness of Combined GLP-1 and GIP TreatmentsThe Effect of Fructose and FTO Gene Polymorphism on the Efficacy of GLP-1 and GIP Combination Therapies: A Narrative Review.

1 month ago • The Lancet regional health. Europe

Why preventing obesity is important even with new GLP-1 treatmentsThe case for primary prevention of obesity in the era of GLP-1 therapies.

🥈 Top 2% Journal

1 month ago • Diabetes, obesity & metabolism

1 month ago • Therapeutic advances in endocrinology and metabolism

Heart health and biomarker changes over 2 years with semaglutide, empagliflozin, and sitagliptin in people with obesity and type 2 diabetesComparative 24-month cardiovascular outcomes and biomarker trajectories with semaglutide, empagliflozin, and sitagliptin in people with obesity and type 2 diabetes: a multicenter real-world study.

🎖️ Top 10% Journal

1 month ago • Circulation

Lowering Heart Disease Risk with GLP-1 Receptor Agonist DrugsCardiovascular Risk Reduction With GLP-1 RA Drugs.

🥇 Top 1% Journal

1 month ago • Endocrine, metabolic & immune disorders drug targets

Semaglutide's possible impact on muscle and bone health linked to GLP-1 receptor levelsSemaglutide and Musculoskeletal Health: A Mendelian Randomization Study Based on GLP-1 Receptor Expression.

📖 Top 50% Journal

1 month ago • Diabetes, obesity & metabolism

Tirzepatide’s real-world effects and safety in type 1 diabetes and obesity, including blood sugar, weight, and heart health markersReal-World Effectiveness and Safety of Tirzepatide in Type 1 Diabetes and Obesity: Impact on Glycaemia, Weight, and Cardiometabolic Risk Markers.

1 month ago • The journal of allergy and clinical immunology. Global

📖 Top 20% Journal

1 month ago • Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery

GLP-1 Receptor Agonist Linked to Disease Severity in Unexplained Narrowing Below the Voice BoxGLP-1 Receptor Agonist Effect on Disease Severity in Idiopathic Subglottic Stenosis.

📖 Top 20% Journal

1 month ago • Biomolecular concepts

Recent advances in the molecules, genes, and treatments of type 2 diabetes (2015-2025)Molecular, genetic, and pharmacological advances in type 2 diabetes (2015-2025).

📖 Top 50% Journal

1 month ago • European heart journal open

Addiction as a heart and metabolism disease: a brain-heart-metabolism perspective and the growing role of GLP-1 receptor treatmentsAddiction as a cardiometabolic disease: a neurocardiometabolic framework and the emerging role of GLP-1 receptor therapies.

🎖️ Top 10% Journal

1 month ago • JAMA

Online Prescribing of Diabetes and Weight Loss MedicationsOnline Prescribing of GLP-1 Receptor Agonists.

1 month ago • Diabetes, obesity & metabolism

A molecule that first activates then blocks two hormone receptors leads to greater weight loss in obese miceA Sequential Dual GLP-1R/GIPR Agonist-To-Antagonist Molecule Achieves Superior Weight Loss in Obese Mice.

← prevpage 14 of 15next →

Latest GLP-1 Therapies Research Papers